---
title: "Director’s Major Stock Sale Shakes Up Kymera Therapeutics"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/269585044.md"
description: "Director Bruce Booth sold 236,588 shares of Kymera Therapeutics (KYMR) for $21.7M on December 12, 2025. Analysts have raised KYMR's stock price targets due to positive clinical trial results and FDA Fast Track designation for KT-621. Despite poor financial performance, strong technical indicators and positive corporate events provide some optimism. KYMR's YTD price performance is 114.75%, with a market cap of $6.47B."
datetime: "2025-12-13T02:10:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269585044.md)
  - [en](https://longbridge.com/en/news/269585044.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269585044.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/269585044.md) | [English](https://longbridge.com/en/news/269585044.md)


# Director’s Major Stock Sale Shakes Up Kymera Therapeutics

New insider activity at Kymera Therapeutics ( (KYMR) ) has taken place on December 12, 2025.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Director Bruce Booth has made a significant move by selling 236,588 shares of Kymera Therapeutics stock, amounting to a substantial $21,699,043.

**Recent Updates on KYMR stock**

Kymera Therapeutics has seen a significant increase in its stock price targets from several analysts following positive developments in its clinical trials and regulatory progress. The company’s KT-621, an oral STAT6 degrader, received Fast Track designation from the FDA for treating moderate to severe atopic dermatitis, which has been a key factor in the raised price targets. Analysts from Stephens, Mizuho, and JPMorgan have all increased their price targets, citing the compelling efficacy and safety profile demonstrated in the Phase 1b BroADen trial, which de-risks the program and increases the probability of success in future trials for atopic dermatitis and asthma. These developments, along with a major stock offering, are expected to enhance Kymera’s market position and support its operations into the future.

**Spark’s Take on KYMR Stock**

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera Therapeutics’ overall stock score is primarily impacted by its poor financial performance, which is a significant concern. However, strong technical indicators and positive corporate events provide some optimism. The earnings call also suggests strategic progress, but high expenses and valuation concerns remain.

To see Spark’s full report on KYMR stock, click here.

**More about Kymera Therapeutics**

**YTD Price Performance:** 114.75%

**Average Trading Volume:** 966,077

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $6.47B

### 相關股票

- [Kymera Therapeutics (KYMR.US)](https://longbridge.com/zh-HK/quote/KYMR.US.md)

## 相關資訊與研究

- [Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock](https://longbridge.com/zh-HK/news/281546235.md)
- [Kymera Therapeutics Updates Bylaws on Federal Securities Litigation](https://longbridge.com/zh-HK/news/280850528.md)
- [Is Taysha (TSHA) Recasting Its Rett Strategy With New Market Access Hire After Wider Losses?](https://longbridge.com/zh-HK/news/281500622.md)
- [Galderma - Nemolizumab data demonstrate benefits for children moderate-to-severe atopic dermatitis](https://longbridge.com/zh-HK/news/280958963.md)
- [02:23 ETEMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)](https://longbridge.com/zh-HK/news/280965130.md)